Is A a good stock to buy?
Agilent Technologies, Inc. · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 22
- MAs3 of 4
- Sector▲ +15.9%
- Earnings in10d
- P/E34.2x
- RSI51
- Support-2.6%
- Off 52w high-4.9%
- Volume0.7x
- Bollingerlower half
- News0.00
- FCF yield+2.6%
- P/E vs sector+6.3%
- PT$174.29 +0.2%
- Trendsideways
- 52w range$108–$183
- ATR+2.9%
- Off ATH-4.9%
- MA20×50↓ in ~22d
- P/E vs own+22.3%
- Insiders-$95.97K
- MACD-0.79
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Agilent a good stock to buy?
Agilent is strong on 3 of the 5 questions about the business. The price is high: 34.2 times its earnings, above its 3-year median of 29.4 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage hard to copy
- Economics very profitable
- Execution mixed
- Fragility sturdy
- Price expensive
A sales growth revenue growth
0%a year, for the last 3 yearsAgilent's sales grew 0% a year for 3 years, to $6.95B in fiscal 2025.
A analysts' forecast revenue estimates
+8%the sales they expect next fiscal year, on the lastAnalysts expect Agilent's sales to grow 8% to $7.5B in fiscal 2026 (15 analysts).
A competitors
pretickt analysis+9%its sales in 12 months, on a year before
Agilent's sales grew 9% in the 12 months to Jul 31, 2026, slower than Waters (+81%), Natera (+37%), Idexx Laboratories (+12%) and IQVIA (+9%).
A sales by business revenue by segment
42%of its sales from Agilent CrossLabAgilent CrossLab brought Agilent 42% of its sales in fiscal 2025; Life Sciences and Applied Markets 39%.
A return on capital ROIC
pretickt analysis17%earned before tax on the money invested in itAgilent earned 17% before tax on the capital invested in it in the 12 months to Jul 31, 2026; Idexx Laboratories 74%, IQVIA 11%, Waters 2% and Natera -26%.
A margin on each sale gross margin
54%left after making the productAgilent kept 54% of each sale after making the product in the 12 months to Jul 31, 2026; its competitors' median is 56%.
A margin after costs profit margin
22%of sales left after running the businessAgilent's operating margin was 22% in the 12 months to Jul 31, 2026, against 24% in fiscal 2022.
A cash generated free cash flow
$1.27Bcash left after investing, last 12 monthsAgilent generated $1.27B of free cash flow in the 12 months to Jul 31, 2026, less than its reported profit.
A earnings vs estimates
6 of 8quarters above the analysts' estimateAgilent beat the analysts' profit estimate in 6 of its last 8 quarters, the latest on Aug 26, 2026.
A insider selling
-$1.3Msold, net, by its executives in 12 monthsAgilent's executives and directors sold a net $1.3M of shares in the 12 months to Nov 13, 2026; none bought.
A number of employees
+1%more people in a yearAgilent had 18,100 employees at the end of fiscal 2025, 1% more than a year before.
A CEO pay
$12.83Mfor fiscal 2025, 79% of it in stock and optionsAgilent paid its CEO $12.83M for fiscal 2025, 79% of it in stock and options.
A financial health Altman Z-score
5.8Altman Z-score, safe above 3Agilent's Altman Z-score is 5.8 (Nov 13, 2026), above 3, where the safe zone starts.
A quality checks Piotroski score
7 of 9checks passedAgilent passes 7 of the 9 Piotroski checks in the 12 months to Jul 31, 2026; it misses on the current ratio and sales for its assets.
A biggest customers
under 10%of sales from any one customerNo customer made 10% of Agilent's sales in fiscal 2025.
A in past recessions
pretickt analysis-22%its sales in the worst oneAgilent's sales fell in 1 of the last 2 US recessions, by as much as 22% in fiscal 2009.
A price vs profit P/E ratio
34.2×a year's earningsAgilent's P/E ratio is 34.2 (Nov 13, 2026), above its 3-year median of 29.4.
A price vs competitors
pretickt analysis34.2×a year's earnings, against its competitorsInvestors pay 34.2 times Agilent's earnings (Nov 13, 2026), more than for IQVIA (32.2), less than for Waters (197.5) and Idexx Laboratories (47.8).
A analysts' target price target
0%to their average targetAnalysts' average price target for Agilent is $174, 0% above the Nov 13, 2026 close of $173.96.
A growth priced in fair value
pretickt analysis+16%a year, for ten years, to be worth the priceAt $173.96 a share, Agilent's free cash flow must grow about 16% a year for ten years to be worth the price (Nov 13, 2026).
What is Agilent's P/E ratio?
Agilent's P/E ratio is 34.2 (Nov 13, 2026), above its 3-year median of 29.4. Investors pay 34.2 times Agilent's earnings (Nov 13, 2026), more than for IQVIA (32.2), less than for Waters (197.5) and Idexx Laboratories (47.8).
Who are Agilent's biggest competitors?
pretickt compares Agilent with Natera, Waters, IQVIA and Idexx Laboratories. Agilent's sales grew 9% in the 12 months to Jul 31, 2026, slower than Waters (+81%), Natera (+37%), Idexx Laboratories (+12%) and IQVIA (+9%).
Is Agilent profitable?
Agilent's operating margin was 22% in the 12 months to Jul 31, 2026, against 24% in fiscal 2022. Agilent generated $1.27B of free cash flow in the 12 months to Jul 31, 2026, less than its reported profit.
Are insiders selling Agilent stock?
Agilent's executives and directors sold a net $1.3M of shares in the 12 months to Nov 13, 2026; none bought.
How does Agilent make money?
Agilent CrossLab brought Agilent 42% of its sales in fiscal 2025; Life Sciences and Applied Markets 39%.
How many employees does Agilent have?
Agilent had 18,100 employees at the end of fiscal 2025, 1% more than a year before.
Who are Agilent's biggest customers?
No customer made 10% of Agilent's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.